Moody's: McKesson notes Baa2

Moody's Investors Service assigned a Baa2 to McKesson Corp.'s new senior note offering.

Moody's affirmed the Baa2 senior notes, Prime-2 short-term rating and Baa2 backed industrial revenue bonds.

Proceeds will be used to refinance debt assumed in conjunction with the December 2010 acquisition of US Oncology Holdings, Inc.

Moody's affirmed McKesson's existing ratings (Baa2/Prime-2) and stable outlook.

The ratings consider the business risk and competitive position of the company versus others within its industry, the capital structure and financial risk of the company, the projected performance of the company over the near to intermediate term and management's track record and tolerance for risk, Moody's said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.